News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Second-Hand Asbestos Exposure Responsible for Some Mesothelioma Cases
- Lab-on-Bead Offers Potential to Quickly Develop New Treatment for Mesothelioma
- “Rock for Doc” Concert Held to Raise Money for Doctor’s Mesothelioma Treatments
- NY Mesothelioma and Asbestos Attorney Applauds Changes to City’s Building Inspection Oversight
- Mesothelioma Patient Cancer-Free Five Years After Innovative Treatment
- University of Arizona’s Cancer Center Hopes to Become Premier Mesothelioma Treatment Facility in the Southwest
- SBRT, Useful for Treating Mesothelioma, to be Discussed at 2010 ASTRO Conference
- British Man Fights Mesothelioma by Running
- Ogdensburg Receives Grant Money to Demolish Buildings Known to Contain Mesothelioma-Causing Asbestos
- ADI-PEG 20 Shows Promise in Inhibiting Mesothelioma Cancer Cell Growth
Monday, March 8, 2010
Reasearchers in the Netherlands, using a special type of cell known as a dendritic cell that is a key regulator in the immune system, have created an immunotherapy treatment against mesothelioma. They hope the research will one day lead to a vaccine for people who have been exposed to asbestos to help prevent asbestos-related diseases.
Mesothelioma is a rare form of cancer typically affecting the lining of the lungs. Primarily caused by exposure to airborne asbestos fibers, most cases of mesothelioma are diagnosed 30 years or more after exposure. The latency period can be as long as 50 years.
Immunotherapy uses the body’s own immune system to target and destroy cancer cells. The aim of immunotherapy is to harness the strength of the immune system in a specifically focused attack on cancer cells, while avoiding the broader toxic effects of chemotherapy.
The researchers tested the vaccine on 10 patients achieving 80 percent effectiveness. The results generated an immune T-cell response against the mesothelioma tumors. T-cells assist other white blood cells in immunologic processes. Treatment is a series of three vaccinations given over a two week period after receiving chemotherapy.
“This is the first human study on dendritic cell-based immunotherapy in patients with mesothelioma,” said Dr. Joachim Aerts, a pulmonary physician at Erasmus Medical Center in the Netherlands and lead author of a study published online in the American Thoracic Society’s Journal of Respiratory and Critical Care Medicine.
While the size of the study was small, the researchers said the results suggest that selected patients may benefit from dendritic cell immunotherapy without major adverse effects.
© MesotheliomaHelp.Net. All Rights Reserved. Reprinting or republication of this article or any portion of its content is permitted but must include the MesotheliomaHelp.Net link.
Labels: mesothelioma, Research News
posted by Nancy Meredith at 7:20 AM
